N C Millan1, M J Poveda1, O Cruz1, J Mora2. 1. Department of Pediatric Hematology and Oncology, Hospital Sant Joan de Déu de Barcelona, Passeig de Sant Joan de Déu num 2, Esplugues del Llobregat, 08950, Barcelona, Spain. 2. Department of Pediatric Hematology and Oncology, Hospital Sant Joan de Déu de Barcelona, Passeig de Sant Joan de Déu num 2, Esplugues del Llobregat, 08950, Barcelona, Spain. jmora@hsjdbcn.org.
Abstract
PURPOSE: Limited data exist regarding the safety and efficacy of bevacizumab in pediatric patients under the age of 4 years. Here, we report a large cohort of pediatric patients under 4 years of age treated with bevacizumab. METHODS: The primary objective was to document adverse events with a possible relationship to bevacizumab. Patients (n = 16) were identified through retrospective chart review and harbored a variety of conditions (44% central nervous system (CNS) tumors, 31% vascular anomalies, 13% neuroblastoma, 12% other). RESULTS: The median age was 34.3 months (range 4.9-47.3), including five patients <2 years of age. Patients received bevacizumab for a median duration of 6.2 months, alone or with chemotherapy, and a median dose of 9.25 mg/kg (range 7.0-11.8). Partial responses were seen in 19% of patients, and clinical improvements were seen in 69%. Adverse events known to be associated with bevacizumab occurred in 37%. Outcomes observed in this population resemble those reported for bevacizumab in older pediatric patients. The overall pattern and frequency of adverse events observed was similar to those seen in reports of older pediatric patients with a variety of conditions. The highest level of efficacy observed was seen among patients with vascular malformations or with low-grade CNS tumors. CONCLUSIONS: Our results suggest that the use of bevacizumab is safe for the youngest children.
PURPOSE: Limited data exist regarding the safety and efficacy of bevacizumab in pediatric patients under the age of 4 years. Here, we report a large cohort of pediatric patients under 4 years of age treated with bevacizumab. METHODS: The primary objective was to document adverse events with a possible relationship to bevacizumab. Patients (n = 16) were identified through retrospective chart review and harbored a variety of conditions (44% central nervous system (CNS) tumors, 31% vascular anomalies, 13% neuroblastoma, 12% other). RESULTS: The median age was 34.3 months (range 4.9-47.3), including five patients <2 years of age. Patients received bevacizumab for a median duration of 6.2 months, alone or with chemotherapy, and a median dose of 9.25 mg/kg (range 7.0-11.8). Partial responses were seen in 19% of patients, and clinical improvements were seen in 69%. Adverse events known to be associated with bevacizumab occurred in 37%. Outcomes observed in this population resemble those reported for bevacizumab in older pediatric patients. The overall pattern and frequency of adverse events observed was similar to those seen in reports of older pediatric patients with a variety of conditions. The highest level of efficacy observed was seen among patients with vascular malformations or with low-grade CNS tumors. CONCLUSIONS: Our results suggest that the use of bevacizumab is safe for the youngest children.
Entities:
Keywords:
Antiangiogenesis; Bevacizumab; Infant and toddlers; Infant tumors
Authors: Fariba Navid; Sharyn D Baker; M Beth McCarville; Clinton F Stewart; Catherine A Billups; Jianrong Wu; Andrew M Davidoff; Sheri L Spunt; Wayne L Furman; Lisa M McGregor; Shuiying Hu; John C Panetta; David Turner; Demba Fofana; Wilburn E Reddick; Wing Leung; Victor M Santana Journal: Clin Cancer Res Date: 2012-11-08 Impact factor: 12.531
Authors: Christopher H Hsu; Robert M Lober; Matthew D Li; Sonia Partap; Patricia A Murphy; Patrick D Barnes; Paul G Fisher; Kristen W Yeom Journal: J Neurooncol Date: 2015-03-11 Impact factor: 4.130
Authors: Ashwatha Narayana; Deborah Gruber; Saroj Kunnakkat; John G Golfinos; Erik Parker; Shahzad Raza; David Zagzag; Patricia Eagan; Michael L Gruber Journal: J Neurosurg Date: 2011-10-28 Impact factor: 5.115
Authors: Maria Debora de Pasquale; Aurora Castellano; Luigi de Sio; Clementina de Laurentis; Angela Mastronuzzi; Annalisa Serra; Raffaele Cozza; Alessandro Jenkner; Maria Antonietta de Ioris Journal: Anticancer Res Date: 2011-11 Impact factor: 2.480
Authors: Dolly Aguilera; Claire Mazewski; Jason Fangusaro; Tobey J MacDonald; Rene Y McNall-Knapp; Laura L Hayes; Sungjin Kim; Robert C Castellino Journal: Childs Nerv Syst Date: 2013-01-08 Impact factor: 1.475
Authors: Amalia Schiavetti; Annapaola Ingrosso; Anna Antenucci; Tatiana Federici; Giacomina Megaro; Laura De Luca; Laura Conti Journal: Anticancer Res Date: 2012-08 Impact factor: 2.480
Authors: Shakeel Modak; Brian H Kushner; Ellen Basu; Stephen S Roberts; Nai-Kong V Cheung Journal: Pediatr Blood Cancer Date: 2017-01-23 Impact factor: 3.167